Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer

被引:12
|
作者
Musoro, Jammbe Z. [1 ]
Coens, Corneel [1 ]
Greimel, Elfriede [2 ]
King, Madeleine T. [3 ]
Sprangers, Mirjam A. G. [4 ]
Nordin, Andy [5 ]
van Dorst, Eleonora B. L. [6 ]
Groenvold, Mogens [7 ]
Cocks, Kim [8 ]
Velikova, Galina [9 ]
Flechtner, Hans-Henning [10 ]
Bottomley, Andrew [1 ]
机构
[1] European Org Res & Treatment Canc EORTC, Brussels, Belgium
[2] Med Univ Graz, Graz, Austria
[3] Univ Sydney, Fac Sci, Sch Psychol, Sydney, NSW, Australia
[4] Univ Amsterdam, Amsterdam Univ Med Ctr, Locat Acad Med Ctr, Canc Ctr Amsterdam,Dept Med Psychol, Amsterdam, Netherlands
[5] Queen Elizabeth Queen Mother Hosp, East Kent Gynaecol Oncol Ctr, Margate, England
[6] Acad Hosp Utrecht, Dept Obstet & Gynecol, Utrecht, Netherlands
[7] Univ Copenhagen, Bispebjerg Hosp, Dept Publ Hlth, Copenhagen, Denmark
[8] Adelphi Values, Bollington, Cheshire, England
[9] Univ Leeds, Leeds Inst Med Res & St Jamess, Leeds, W Yorkshire, England
[10] Univ Magdeburg, Clin Child & Adolescent Psychiat & Psychotherapy, Magdeburg, Germany
关键词
Health-related quality of life (HRQOL); EORTC QLQ-C30; Minimally important difference (MID); Ovarian cancer; OUTCOMES; QLQ-C30;
D O I
10.1016/j.ygyno.2020.09.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Minimal important differences (MIDs) are useful for interpreting changes or differences in health-related quality of life scores in terms of clinical importance. There are currently no MID guidelines for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) specific to ovarian cancer. This study aims to estimate MIDs for interpreting group-level change of EORTC QLQ-C30 scores in ovarian cancer. Methods. Data were derived from four EORTC published trials. Clinical anchors for each EORTC QLQ-C30 scale were selected using correlation strength and clinical plausibility. MIDs for within-group change and between-group differences in change over time were estimated via mean change method and linear regression respectively. For each EORTC QLQ-C30 scale, MID estimates from multiple anchors were summarized via weighted-correlation. Distribution-based MIDs were also examined as supportive evidence. Results. Anchor-based MIDs were determined for deterioration in 7 of the 14 EORTC QLQ-C30 scales assessed, and in 11 scales for improvement. Anchor-based MIDs for within-group change ranged from 4 to 19 (improvement) and - 9 to -4 (deterioration). Between-group MIDs ranged from 3 to 13 (improvement) and - 11 to -4 (deterioration). Generally, absolute anchor-based MIDs for most scales ranged from 4 to 10 points. Conclusions. Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:515 / 521
页数:7
相关论文
共 50 条
  • [1] Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer
    Musoro, Jammbe Z.
    Coens, Corneel
    Singer, Susanne
    Tribius, Silke
    Oosting, Sjoukje F.
    Groenvold, Mogens
    Simon, Christian
    Machiels, Jean-Pascal
    Gregoire, Vincent
    Velikova, Galina
    Cocks, Kim
    Sprangers, Mirjam A. G.
    King, Madeleine T.
    Bottomley, Andrew
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (11): : 3141 - 3152
  • [2] Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma
    Musoro, Jammbe Z.
    Bottomley, Andrew
    Coens, Corneel
    Eggermont, Alexander M. M.
    King, Madeleine T.
    Cocks, Kim
    Sprangers, Mirjam A. G.
    Groenvold, Mogens
    Velikova, Galina
    Flechtner, Hans-Henning
    Brandberg, Yvonne
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 104 : 169 - 181
  • [3] Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
    Cocks, K.
    King, M. T.
    Velikova, G.
    de Castro, G., Jr.
    St-James, M. Martyn
    Fayers, P. M.
    Brown, J. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (11) : 1713 - 1721
  • [4] Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer
    Musoro, Jammbe Z.
    Coens, Corneel
    Fiteni, Frederic
    Katarzyna, Pogoda
    Cardoso, Fatima
    Russell, Nicola S.
    King, Madeleine T.
    Cocks, Kim
    Sprangers, Mirjam Ag
    Groenvold, Mogens
    Velikova, Galina
    Flechtner, Hans-Henning
    Bottomley, Andrew
    [J]. JNCI CANCER SPECTRUM, 2019, 3 (03)
  • [5] The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Endometrial Cancer: EORTC QLQ-EN24
    Singer, Susanne
    Greimel, Elfriede
    [J]. QUALITY OF LIFE RESEARCH, 2010, 19 : 90 - 91
  • [6] Minimally important difference (MID) in scores on the European organization for research and treatment of cancer (EORTC) Quality of Life Questionnaire Core 15 for Palliative (QLQ-C15-PAL)
    Miyazaki, Kikuko
    Suzukamo, Yoshimi
    Shimozuma, Kojiro
    Ohsumi, Shozo
    Saito, Mari
    Nakayama, Takeo
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 : 36 - 36
  • [7] Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies
    Efficace, Fabio
    Cottone, Francesco
    Sommer, Kathrin
    Kieffer, Jacobien
    Aaronson, Neil
    Fayers, Peter
    Groenvold, Mogens
    Caocci, Giovanni
    Lo Coco, Francesco
    Gaidano, Gianluca
    Niscola, Pasquale
    Baccarani, Michele
    Rosti, Gianantonio
    Venditti, Adriano
    Angelucci, Emanuele
    Fazi, Paola
    Vignetti, Marco
    Giesinger, Johannes
    [J]. VALUE IN HEALTH, 2019, 22 (11) : 1303 - 1310
  • [8] Die Lebensqualitätsfragebögen der European Organisation for Research and Treatment of Cancer (EORTC)Aktuelle EntwicklungenThe quality of life questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC)Current developments
    D. Hofmeister
    S. Singer
    [J]. Forum, 2013, 28 (1) : 35 - 38
  • [9] Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessment in patients with ovarian cancer
    Howat, S
    Cull, A
    Greimel, E
    Waldenstrom, AC
    Arraras, AC
    Kudelka, A
    Chauvenet, L
    [J]. PSYCHO-ONCOLOGY, 1998, 7 (01) : 61 - 61
  • [10] MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS
    Musoro, Z. J.
    Coens, C.
    Fiteni, F.
    Pogoda, K.
    Cardoso, F.
    Tribius, S.
    Singer, S.
    Oosting, S.
    Russell, N.
    Simon, C.
    Jean-Pascal, M.
    Gregoire, V
    Velikova, G.
    King, M. T.
    Gronvold, M.
    Cocks, K.
    Sprangers, M.
    Eggermont, A.
    Brandberg, Y.
    Bottomley, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S78 - S78